journal
MENU ▼
Read by QxMD icon Read
search

Current Heart Failure Reports

journal
https://www.readbyqxmd.com/read/27900617/new-and-evolving-concepts-regarding-the-prognosis-and-treatment-of-cardiac-amyloidosis
#1
REVIEW
Stefano Perlini, Roberta Mussinelli, Francesco Salinaro
Systemic amyloidoses are rare and proteiform diseases, caused by extracellular accumulation of insoluble misfolded fibrillar proteins. Prognosis is dictated by cardiac involvement, which is especially frequent in light chain (AL) and in transthyretin variants (ATTR, both mutated, (ATTRm), and wild-type, (ATTRwt)). Recently, ATTRwt has emerged as a potentially relevant cause of a heart failure with preserved ejection fraction (HFpEF). Cardiac amyloidosis is an archetypal example of restrictive cardiomyopathy, with signs and symptoms of global heart failure and diastolic dysfunction...
November 29, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27878511/new-challenges-in-the-treatment-of-patients-with-left-ventricular-support-lvad-thrombosis
#2
REVIEW
Ann B Nguyen, Nir Uriel, Sirtaz Adatya
Mechanical circulatory support has revolutionized the treatment of heart failure, affording patients significantly improved survival and quality of life. However, further advancements in this technology have been hindered by adverse events, particularly gastrointestinal bleeding, driveline infection, stroke, and device thrombosis. Recently, there has been a renewed focus on device thrombosis as the reported incidence has increased. This review focuses on an update on the diagnostic modalities and current treatment algorithms of this serious complication...
November 22, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27858232/pulmonary-hypertension-in-heart-failure-patients-pathophysiology-and-prognostic-implications
#3
REVIEW
Marco Guazzi, Valentina Labate
Pulmonary hypertension (PH) due to left heart disease (LHD), i.e., group 2 PH, is the most common reason for increased pressures in the pulmonary circuit. Although recent guidelines incorporate congenital heart disease in this classification, left-sided heart diseases of diastolic and systolic origin including valvular etiology are the vast majority. In these patients, an increased left-sided filling pressure triggers a multistage hemodynamic evolution that ends into right ventricular failure through an initial passive increase in pulmonary artery pressure complicated over time by pulmonary vasoconstriction, endothelial dysfunction, and remodeling of the small-resistance pulmonary arteries...
November 17, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27854009/autonomic-modulation-with-baroreflex-activation-therapy-in-heart-failure
#4
REVIEW
Edoardo Gronda, Emilio Vanoli
Baroreflex activation therapy (BAT) produces a central inhibition of cardiac sympathetic outflow and, concomitantly, an increased cardiac vagal activity via a physiological reflex pathway. In a pilot study in 11 patients with NYHA class III heart failure (HF), BAT produced a persistent significant reduction of muscle sympathetic nerve activity over a 21-month follow-up and a dramatic decrease in the number and length of hospitalizations. In a multinational, prospective, randomized, parallel-controlled, clinical trial in 146 NYHA functional class III HF, BAT produced a significant N-terminal pro-brain natriuretic peptide reduction (p = 0...
November 16, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27817003/obstructive-ventilatory-disorder-in-heart-failure-caused-by-the-heart-or-the-lung
#5
REVIEW
Sergio Caravita, Jean-Luc Vachiéry
Heart failure (HF) is a clinical syndrome frequently associated with airway obstruction, either as a respiratory comorbidity or as a direct consequence of HF pathophysiology. Recognizing the relative contribution of an underlying airway disease as opposed to airway obstruction due to volume overload and left atrial pressure elevation is of importance for the appropriate management of patients affected by HF. This review focuses on "les liaisons dangereuses" between the heart and the lungs, outlying recent advances linking in a vicious circle of chronic obstructive lung disease (COPD) and obstructive sleep apnea (OSA) on one side and HF on the other side...
November 5, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27815681/coagulation-abnormalities-in-heart-failure-pathophysiology-and-therapeutic-implications
#6
REVIEW
Ju H Kim, Palak Shah, Udaya S Tantry, Paul A Gurbel
Heart failure (HF) represents a heterogeneous condition characterized by vulnerabilities in the blood, vasculature, and impaired flow dynamics that predispose to both arterial and venous thrombosis. Despite evidence-based advances in the medical and device management of chronic HF, it remains a leading cause of morbidity and mortality in the USA due to repeat hospitalizations and comorbid conditions such as atrial fibrillation (AF) and stroke. The presence of platelet activation and hypercoagulability in HF has been well documented...
November 4, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27807757/heart-failure-secondary-to-chagas-disease-an-emerging-problem-in-non-endemic-areas
#7
REVIEW
Mahmoud Traina, Sheba Meymandi, Jason S Bradfield
Chagas disease affects millions of people worldwide. Though the majority of infected individuals remain asymptomatic, approximately 30 % of patients progress to develop cardiac manifestations and eventual heart failure. While vectorial transmission occurs predominantly in South America, Central America, and Mexico, millions of people originally from these endemic regions immigrate to non-endemic countries in North America, Europe, and Asia. Outside of rare specialized centers, health-care providers lack experience diagnosing and treating this disease...
November 2, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27696142/contemporary-controversies-in-digoxin-use-in-systolic-heart-failure
#8
Chonyang L Albert, Forum Kamdar, Mazen Hanna
Digoxin remains one of the oldest therapies for heart failure; however, its safety and efficacy have been controversial since its initial use. Questions that remain include the clinical efficacy of digoxin when added to contemporary medical therapy, when and if it should be added, and how to minimize adverse effects. In this review, we will summarize recent data on the use of digoxin in systolic heart failure and address some of the controversies regarding the role of digoxin in the modern era of heart failure treatment...
October 1, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27640202/sleep-disordered-breathing-do-we-have-to-change-gears-in-heart-failure
#9
Martin R Cowie
The majority of patients with heart failure have sleep-disordered breathing (SDB)-with central (rather than obstructive) sleep apnoea becoming the predominant form in those with more severe disease. Cyclical apnoeas and hypopnoeas are associated with sleep disturbance, hypoxaemia, haemodynamic changes, and sympathetic activation. Such patients have a worse prognosis than those without SDB. Mask-based therapies of positive airway pressure targeted at SDB can improve measures of sleep quality and partially normalise the sleep and respiratory physiology, but recent randomised trials of cardiovascular outcomes in central sleep apnoea have been neutral or suggested the possibility of harm, likely from increased sudden death...
September 17, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27726056/biomarkers-to-predict-reverse-remodeling-and-myocardial-recovery-in-heart-failure
#10
Shweta R Motiwala, Hanna K Gaggin
Left ventricular remodeling appears to be a critical link between cardiac injury and the development and progression of heart failure with reduced ejection fraction (HFrEF). Several drug and device therapies that modify and reverse the remodeling process in patients with HFrEF are closely associated with improvement in clinical outcomes. Reverse remodeling, including partial or complete recovery of systolic function and structure, is possible but its determinants are incompletely understood. Methods to predict reverse remodeling in response to therapy are not well defined...
October 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27497715/newer-therapies-for-amyloid-cardiomyopathy
#11
REVIEW
Rajshekhar Chakraborty, Eli Muchtar, Morie A Gertz
The heart and the kidneys are the most commonly involved organs in systemic amyloidosis. Cardiac involvement is associated with an increased morbidity, treatment intolerance, and poorer overall survival. The most common types of amyloidosis that are associated with cardiac involvement include light chain (AL) amyloidosis and transthyretin (TTR) amyloidosis (both mutant and wild type). The traditional first-line treatment for AL amyloidosis includes alkylator-based chemotherapy or high-dose melphalan followed by autologous stem cell transplantation (ASCT)...
October 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27485737/burden-of-heart-failure-in-adults-with-congenital-heart-disease
#12
Laith I Alshawabkeh, Alexander R Opotowsky
Patients born with congenital heart disease (CHD) have benefited from remarkable advances in surgical and catheter-based interventions. As a result, the majority of children born with even the most complex forms of CHD live into adulthood. The specialized field of adult CHD (ACHD) was born out of the necessity to care for this new population of survivors of childhood CHD and their distinctive features. In this review, relevant aspects of ACHD that lead to, and are affected by, heart failure will be examined along with the increasing prevalence of HF in the burgeoning population of ACHD...
October 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27553893/right-ventricular-versus-biventricular-pacing-for-heart-failure-and-atrioventricular-block
#13
Hiroko Beck, Anne B Curtis
The use of cardiac resynchronization therapy (CRT) is well accepted as an important option for the treatment of patients with systolic heart failure and prolonged QRS duration. CRT for patients with narrow QRS complexes is reserved for patients who are undergoing implantation of new or replacement pacemakers or implantable cardioverter defibrillators with an anticipated significant requirement for ventricular pacing. The Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial examined the role of CRT in heart failure patients with atrioventricular block and demonstrated significantly better outcomes with CRT compared to right ventricular pacing...
August 23, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27539049/cardiometabolic-syndrome-and-increased-risk-of-heart-failure
#14
Helene von Bibra, Walter Paulus, Martin St John Sutton
Approximately 50 % of patients with heart failure have diastolic heart failure (HFPEF) with the major predisposing risk factors age, inactivity, obesity, insulin resistance (IR), type-2 diabetes, and hypertension. The prognosis of HFPEF is comparable to that of systolic heart failure, but without any specific or effective treatment. This review presents a biomathematically corrected diagnostic approach for quantification of diastolic dysfunction (DD) via the age dependency of diastolic function. Pathophysiological mechanisms for DD in the cardiometabolic syndrome (CMS) are mainly based on downstream effects of IR including insufficient myocardial energy supply...
August 18, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27333901/coenzyme-q10-and-utility-in-heart-failure-just-another-supplement
#15
REVIEW
Sylvia Oleck, Hector O Ventura
Heart failure affects 5.1 million people in the USA annually. It accounts for a frequent cause of hospitalizations and disability. Patients with congestive heart failure have lower plasma levels of CoQ10, which is an independent predictor of mortality in this patient population. It has been hypothesized that a deficiency of CoQ10 can play a role in the development and worsening of heart failure, and that oral supplementation can possibly improve symptoms and survival in these patients. Based on previous small studies and meta-analyses, the use of CoQ10 in heart failure suggested an improvement ejection fraction, stroke volume, cardiac output, and cardiac index with CoQ10 supplementation, however most of these small studies appeared to be underpowered to result in any significant data...
August 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27287200/exhaled-breath-analysis-in-heart-failure
#16
REVIEW
Fabiana G Marcondes-Braga, Guilherme Lopes Batista, Fernando Bacal, Ivano Gutz
Heart failure (HF) is a clinical condition that presents high morbidity and mortality and is one of the main reasons for hospital admissions all over the world. Although biochemical processes that occur in the body during heart failure are known, this syndrome is still associated to poor prognosis. Exhaled breath analysis has emerged as a promising noninvasive tool in different clinical conditions and, recently, it has been also tested in patients with HF. This review presents the main breath HF biomarkers, which reflect metabolic changes that occur in this complex syndrome...
August 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27278221/pharmacologic-approaches-to-electrolyte-abnormalities-in-heart-failure
#17
REVIEW
Justin L Grodin
Electrolyte abnormalities are common in heart failure and can arise from a variety of etiologies. Neurohormonal activation from ventricular dysfunction, renal dysfunction, and heart failure medications can perturb electrolyte homeostasis which impact both heart failure-related morbidity and mortality. These include disturbances in serum sodium, chloride, acid-base, and potassium homeostasis. Pharmacological treatments differ for each electrolyte abnormality and vary from older, established treatments like the vaptans or acetazolamide, to experimental or theoretical treatments like hypertonic saline or urea, or to newer, novel agents like the potassium binders: patiromer and zirconium cyclosilicate...
August 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27271564/neprilysin-inhibition-as-a-paradigm-shift-in-heart-failure-therapy
#18
REVIEW
Ruth Hsiao, Barry Greenberg
Heart failure is a growing global public health problem. With the aging population, increased risk factors for heart failure development, and better survival after myocardial infarction, the prevalence is only expected to increase in the coming years. Although existing therapies have improved the clinical course of heart failure patients, new approaches are urgently needed to enhance quality of life and reduce morbidity and mortality. However, there has been little progress in the treatment of chronic heart failure in the past decade with only two new drugs approved by the US FDA over this time...
August 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27271563/dietary-nitrate-and-skeletal-muscle-contractile-function-in-heart-failure
#19
REVIEW
Andrew R Coggan, Linda R Peterson
Heart failure (HF) patients suffer from exercise intolerance that diminishes their ability to perform normal activities of daily living and hence compromises their quality of life. This is due largely to detrimental changes in skeletal muscle mass, structure, metabolism, and function. This includes an impairment of muscle contractile performance, i.e., a decline in the maximal force, speed, and power of muscle shortening. Although numerous mechanisms underlie this reduction in contractility, one contributing factor may be a decrease in nitric oxide (NO) bioavailability...
August 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27260315/neprilysin-and-natriuretic-peptide-regulation-in-heart-failure
#20
REVIEW
Antoni Bayes-Genis, Nuria Morant-Talamante, Josep Lupón
Neprilysin is acknowledged as a key player in neurohormonal regulation, a cornerstone of modern drug therapy in chronic heart failure. In the cardiovascular system, neprilysin cleaves numerous vasoactive peptides, some with mainly vasodilating effects (natriuretic peptides, adrenomedullin, bradykinin) and other with mainly vasoconstrictor effects (angiotensin I and II, endothelin-1). For decades, neprilysin has been an important biotarget. Academia and industry have combined active efforts to search for neprilysin inhibitors (NEPIs) that might be useful in clinical practice...
August 2016: Current Heart Failure Reports
journal
journal
40571
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"